HUP0200310A2 - Use of tricyclic pyrazole derivatives for preparing pharmaceutical compositions and the new compounds - Google Patents
Use of tricyclic pyrazole derivatives for preparing pharmaceutical compositions and the new compoundsInfo
- Publication number
- HUP0200310A2 HUP0200310A2 HU0200310A HUP0200310A HUP0200310A2 HU P0200310 A2 HUP0200310 A2 HU P0200310A2 HU 0200310 A HU0200310 A HU 0200310A HU P0200310 A HUP0200310 A HU P0200310A HU P0200310 A2 HUP0200310 A2 HU P0200310A2
- Authority
- HU
- Hungary
- Prior art keywords
- new compounds
- pharmaceutical preparations
- pharmaceutical compositions
- pyrazole derivatives
- preparing pharmaceutical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
A találmány tárgya tirozin- és/vagy szerin/treonin-kinázokaktivitásának gátlására szolgáló általános képletű, részben újvegyületek alkalmazása gyógyszerkészítmények előállítására - aholbizonyos megszorításokkal előnyösen X oxigén- vagy kénatom, adottesetben szubsztítuált metilén- vagy iminocsoport, továbbá szulfinil-,szulfonil- etilén- vagy trimetiléncsoport; R1 hidrogénatom; R2 adottesetben szubsztituált aril- vagy heteroaril-csoport; és R3, R4, R5 és R6 hidrogénatom vagy az aromás gyűrűk szokásosszubsztituenseinek valamelyike, különösen halogénatom vagy adottesetben szubsztituált alkoxi-, amino- vagy karbamoil-csoport. Atalálmány tárgyát képezik még az (I) általános képletű új vegyületekés sóik, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk aprotein-kinázokkal összefüggésbe hozható betegségek, főleg gyulladás,hiperproliferatív betegségek és immunológiai rendellenességekkezelésére szolgáló gyógyszerkészítmények előállítására. ÓThe subject of the invention is the use of partially new compounds with a general formula for inhibiting the activity of tyrosine and/or serine/threonine kinases for the production of pharmaceutical preparations - where, with certain restrictions, X is preferably an oxygen or sulfur atom, optionally a substituted methylene or imino group, and also a sulfinyl, sulfonyl, ethylene, or trimethylene group ; R1 is a hydrogen atom; R2 optionally substituted aryl or heteroaryl; and R 3 , R 4 , R 5 and R 6 are a hydrogen atom or one of the usual substituents of the aromatic rings, especially a halogen atom or an optionally substituted alkoxy, amino or carbamoyl group. The subject of the invention is also the new compounds of general formula (I) and their salts, pharmaceutical preparations containing them and their use for the production of pharmaceutical preparations for the treatment of diseases associated with protein kinases, especially inflammation, hyperproliferative diseases and immunological disorders. HE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10746798P | 1998-11-06 | 1998-11-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200310A2 true HUP0200310A2 (en) | 2002-11-28 |
| HUP0200310A3 HUP0200310A3 (en) | 2002-12-28 |
Family
ID=22316761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200310A HUP0200310A3 (en) | 1998-11-06 | 1999-11-04 | Use of tricyclic pyrazole derivatives for preparing pharmaceutical compositions and the new compounds |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1127051A2 (en) |
| JP (1) | JP2003517447A (en) |
| KR (1) | KR20010086005A (en) |
| CN (1) | CN1335836A (en) |
| AU (1) | AU762992B2 (en) |
| BG (1) | BG105481A (en) |
| BR (1) | BR9915132A (en) |
| CA (1) | CA2350235A1 (en) |
| CZ (1) | CZ20011563A3 (en) |
| HK (1) | HK1042895A1 (en) |
| HU (1) | HUP0200310A3 (en) |
| ID (1) | ID30132A (en) |
| IL (1) | IL142584A0 (en) |
| NO (1) | NO20012219L (en) |
| PL (1) | PL348210A1 (en) |
| SK (1) | SK5282001A3 (en) |
| TR (1) | TR200102277T2 (en) |
| WO (1) | WO2000027822A2 (en) |
| ZA (1) | ZA200103610B (en) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462036B1 (en) | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| US6414011B1 (en) * | 1999-03-26 | 2002-07-02 | Euro-Celtique S.A. | Aryl substituted pyrazoles, and pyrroles, and the use thereof |
| NZ514269A (en) * | 1999-04-06 | 2003-10-31 | Abbott Gmbh & Co | Substituted 1,4-dihydroindeno[1,2-c]pyrazoles useful as inhibitors of tyrosine kinase |
| US6297238B1 (en) | 1999-04-06 | 2001-10-02 | Basf Aktiengesellschaft | Therapeutic agents |
| US20040048844A1 (en) | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
| US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| WO2001077171A2 (en) | 2000-04-05 | 2001-10-18 | Zymogenetics, Inc. | Soluble zalpha11 cytokine receptors |
| US6723730B2 (en) | 2000-07-20 | 2004-04-20 | Neurogen Corporation | Capsaicin receptor ligands |
| ATE295354T1 (en) * | 2000-08-18 | 2005-05-15 | Agouron Pharma | HETEROCYCLIC HYDROXIMINO FLUORENES AND THEIR USE FOR INHIBITING PROTEIN KINASES |
| CA2430376A1 (en) * | 2000-12-08 | 2002-06-13 | David J. Carini | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| BR0212611A (en) | 2001-09-19 | 2004-08-17 | Pharmacia Corp | Substituted pyrazolyl compounds for the treatment of inflammation |
| US6849653B2 (en) | 2001-09-19 | 2005-02-01 | Pharmacia Corporation | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation |
| MXPA04008680A (en) * | 2002-02-19 | 2004-12-06 | Pharmacia Italia Spa | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents. |
| US20060264493A1 (en) * | 2003-02-17 | 2006-11-23 | Ermes Vanotti | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| CA2517885A1 (en) * | 2003-03-07 | 2004-09-23 | Abbott Laboratories | Fused tri and tetra-cyclic pyrazole kinase inhibitors |
| US7320986B2 (en) | 2003-03-07 | 2008-01-22 | Abbott Labortories | Fused tri and tetra-cyclic pyrazole kinase inhibitors |
| JP5064795B2 (en) * | 2003-04-07 | 2012-10-31 | アジェニックス ユーエスエー インク． | Inhibitors, compositions, and related uses for cyclin-dependent kinases |
| AR045037A1 (en) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE. |
| GB0326601D0 (en) * | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
| US7468371B2 (en) | 2004-03-24 | 2008-12-23 | Abbott Laboratories Inc. | Tricyclic pyrazole kinase inhibitors |
| WO2005118543A1 (en) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | Kinase inhibitor and use thereof |
| NZ560448A (en) | 2005-02-16 | 2009-08-28 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
| JP2009519974A (en) * | 2005-12-16 | 2009-05-21 | ジェネンテック・インコーポレーテッド | Tetracyclic kinase inhibitor |
| RU2008131324A (en) | 2005-12-30 | 2010-02-10 | Анакор Фармасьютикалз, Инк. (Us) | WOODEN SMALL MOLECULES |
| DK1988779T5 (en) * | 2006-02-16 | 2016-10-10 | Anacor Pharmaceuticals Inc | SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS |
| EA200802058A1 (en) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | DERIVATIVES OF CYCLO-ALKYLAMINO ACIDS AND THEIR PHARMACEUTICAL COMPOSITIONS |
| RU2547441C2 (en) | 2008-03-06 | 2015-04-10 | Анакор Фармасьютикалз, Инк. | Boron-containing small molecules as anti-inflammatory agents |
| WO2010028005A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| EP2348863A4 (en) | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | Boron-containing small molecules |
| US9346834B2 (en) | 2009-10-20 | 2016-05-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
| WO2011059784A1 (en) | 2009-10-29 | 2011-05-19 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds |
| US8461134B2 (en) | 2009-11-11 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| US8623911B2 (en) | 2010-03-19 | 2014-01-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agent |
| SG10201507032YA (en) | 2010-09-07 | 2015-10-29 | Anacor Pharmaceuticals Inc | Benzoxaborole derivatives for treating bacterial infections |
| US8853207B2 (en) | 2012-04-12 | 2014-10-07 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
| CN102675326B (en) * | 2012-04-26 | 2014-08-20 | 华东理工大学 | Preparation method of 3,4-dihydrobenzene benzopyran [3,4-c] pyrazole tricyclic compound |
| EP2909212B1 (en) * | 2012-09-07 | 2017-02-22 | Takeda Pharmaceutical Company Limited | Substituted 1,4-dihydropyrazolo[4,3-b]indoles |
| US9497970B2 (en) * | 2013-07-15 | 2016-11-22 | Basf Se | Pesticide compounds |
| WO2016113261A1 (en) * | 2015-01-13 | 2016-07-21 | Basf Se | Fused tricyclic compounds, compositions comprising these compounds and their use for con-trolling invertebrate pests |
| CN105884828A (en) * | 2015-02-16 | 2016-08-24 | 上海迪诺医药科技有限公司 | Polycyclic compound, pharmaceutical composition and application thereof |
| WO2018045149A1 (en) | 2016-09-02 | 2018-03-08 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| BR112019010629B1 (en) | 2016-11-28 | 2022-11-01 | Sumitomo Chemical Company, Limited | COMPOUND, METHOD FOR CONTROLLING A PEST, USE OF THE COMPOUND, AND COMPOSITION |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2021115560A1 (en) * | 2019-12-09 | 2021-06-17 | Rottapharm Biotech S.R.L. | New fyn and vegfr2 kinase inhibitors |
| CN113773258B (en) * | 2020-06-09 | 2023-08-25 | 兰州大学 | Human LRRK2 protein small molecule inhibitor and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3843665A (en) * | 1973-04-11 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
| JPS60130521A (en) * | 1983-12-19 | 1985-07-12 | Morishita Seiyaku Kk | Anticancer agent |
| BR9611210A (en) * | 1995-10-23 | 1999-12-28 | Zymogenetics Inc | Compositions and processes for treating deficient bone conditions |
| ES2206997T3 (en) * | 1997-10-06 | 2004-05-16 | ABBOTT GMBH & CO. KG | DERIVATIVES OF INDENO (1,2-C) -, OF NAFTO (1,2-C), AND OF BENZO (6,7) CICLOEPTA (1,2-C) PIRAZOL. |
| CN1278724A (en) * | 1997-10-06 | 2001-01-03 | 巴斯福股份公司 | Indeno [1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activty |
-
1999
- 1999-11-04 PL PL99348210A patent/PL348210A1/en not_active Application Discontinuation
- 1999-11-04 SK SK528-2001A patent/SK5282001A3/en unknown
- 1999-11-04 JP JP2000581002A patent/JP2003517447A/en active Pending
- 1999-11-04 ID IDW00200101001A patent/ID30132A/en unknown
- 1999-11-04 WO PCT/US1999/026105 patent/WO2000027822A2/en not_active Application Discontinuation
- 1999-11-04 TR TR2001/02277T patent/TR200102277T2/en unknown
- 1999-11-04 BR BR9915132-4A patent/BR9915132A/en not_active IP Right Cessation
- 1999-11-04 CA CA002350235A patent/CA2350235A1/en not_active Abandoned
- 1999-11-04 AU AU19091/00A patent/AU762992B2/en not_active Ceased
- 1999-11-04 HU HU0200310A patent/HUP0200310A3/en unknown
- 1999-11-04 CN CN99814744A patent/CN1335836A/en active Pending
- 1999-11-04 EP EP99962700A patent/EP1127051A2/en not_active Withdrawn
- 1999-11-04 CZ CZ20011563A patent/CZ20011563A3/en unknown
- 1999-11-04 KR KR1020017005726A patent/KR20010086005A/en not_active Application Discontinuation
- 1999-11-04 IL IL14258499A patent/IL142584A0/en unknown
-
2001
- 2001-04-27 BG BG105481A patent/BG105481A/en unknown
- 2001-05-04 ZA ZA200103610A patent/ZA200103610B/en unknown
- 2001-05-04 NO NO20012219A patent/NO20012219L/en not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104091.8A patent/HK1042895A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000027822A3 (en) | 2000-08-10 |
| TR200102277T2 (en) | 2002-01-21 |
| CZ20011563A3 (en) | 2003-02-12 |
| ID30132A (en) | 2001-11-08 |
| NO20012219D0 (en) | 2001-05-04 |
| CN1335836A (en) | 2002-02-13 |
| NO20012219L (en) | 2001-06-13 |
| PL348210A1 (en) | 2002-05-06 |
| ZA200103610B (en) | 2002-09-23 |
| CA2350235A1 (en) | 2000-05-18 |
| SK5282001A3 (en) | 2002-01-07 |
| HK1042895A1 (en) | 2002-08-30 |
| JP2003517447A (en) | 2003-05-27 |
| AU762992B2 (en) | 2003-07-10 |
| HUP0200310A3 (en) | 2002-12-28 |
| KR20010086005A (en) | 2001-09-07 |
| AU1909100A (en) | 2000-05-29 |
| BG105481A (en) | 2001-12-29 |
| BR9915132A (en) | 2001-08-07 |
| IL142584A0 (en) | 2002-03-10 |
| EP1127051A2 (en) | 2001-08-29 |
| WO2000027822A2 (en) | 2000-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0200310A2 (en) | Use of tricyclic pyrazole derivatives for preparing pharmaceutical compositions and the new compounds | |
| HUP0303164A2 (en) | Quinazolines as mmp-13 inhibitors, process for their preparation, their intermediates and pharmaceutical compositions containing them | |
| EA200000842A1 (en) | BICYCLO [2.2.1] HEPTANS AND RELATED CONNECTIONS | |
| HUP0204245A2 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0401009A2 (en) | 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401339A2 (en) | Novel 4-anilinoquinoline-3-carboxamides, process for their preparation and pharmaceutical compositions containing them | |
| HUP0003073A2 (en) | Benzenesulfonamide derivatives, process for producing them and their use as medicines | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| NO955074L (en) | 1-substituted istain and oxindole derivatives as inhibitors of acetylcholinesterase | |
| HUP0104188A2 (en) | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors | |
| HUP0402191A2 (en) | Acetylene derivatives having human matabotropic glutamate receptor antagonistic activity, process for producing them, pharmaceutical compositions containing them and use thereof | |
| HUP0002843A2 (en) | New betha-carboline compounds, a process for their preparation and pharmaceutical compositions containing them | |
| ATE264846T1 (en) | SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR TREATING RETROVIRAL INFECTIONS | |
| HUP9902471A2 (en) | Piperazine and piperidine compounds, process for their preparation and pharmaceutical compositions containing the same | |
| DE60204452D1 (en) | [1,5] pyridine derivatives | |
| HUP0300618A2 (en) | Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
| HUP0001446A2 (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinone derivatives as hiv reverse transcriptase inhibitors, their use and pharmaceutical compositions containing them | |
| HUP0102723A2 (en) | New diphenylurea derivatives, process for their preparation and pharmaceutical compositions containing them | |
| BR0214024A (en) | 1,2,4-thiadiazole derivatives as melanocortin receptor modulators | |
| TR200200778T2 (en) | Pyrazole derivatives. | |
| HUP0002853A2 (en) | 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them | |
| HUP0201356A2 (en) | Use of estrogen agonists/antagonists for producing pharmaceutical composition useful for treating depression or preventing deterioration of cognitive function | |
| ATE251624T1 (en) | GRANULATIMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | |
| DE69401716T2 (en) | IMIDAZO [1,2-A] PYRASIN-4-ON DERIVATIVES, WHICH SERVE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | |
| HUP0302115A2 (en) | 1,4-diazabicyclo[3.2.2]nonane-phenylisoxazole derivatives, preparation and pharmaceutical compositions thereof |